H7N9 Influenza Clinical Trial
Official title:
Immunogenicity and Safety of an Alum-adjuvanted Inactivated H7N9 Influenza Vaccine: a Randomized, Blind, Placebo-controlled, a Phase II Clinical Trial
The aim of this study is to investigate the immunogenicity and safety of the inactivated
whole-virion vaccine for teenagers and adults.
The investigators will test the vaccine in participants aged above 12 years, for a
randomized, blind, placebo-controlled, clinical study. The investigators designed one dosage
groups: 15 μg of hemagglutinin antigen. Control group is designed to inoculate seasonal
influence vaccine and aluminum hydroxide adjuvant. Participants will receive 2 doses of
vaccine at 21-day intervals. Safety up to 6 months and changes in hemagglutinin inhibition
(HI) titers at 21 days after each vaccination will be determined.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03330899 -
Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil
|
Phase 1 | |
| Not yet recruiting |
NCT06417853 -
Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP)
|
Phase 1 | |
| Active, not recruiting |
NCT03369808 -
A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza Vaccine
|
Phase 1/Phase 2 | |
| Completed |
NCT01928472 -
Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years
|
Phase 1 |